Elicio Therapeutics, INC Form 4 insider transactions

Director Jay Venkatesan exercised pre-funded warrants to acquire 50,000 shares of Elicio Therapeutics common stock at a price of $0.01 per share.

Karen Wilson, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Director Julian Adams of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.

Director Carol Gail Ashe of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.

Jay Venkatesan, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Robert Ruffolo, a director at Elicio Therapeutics, was granted stock options for 4,100 shares on November 21, 2024.

Yekaterina Chudnovsky, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Allen Nissenson, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Robert Connelly, CEO of Elicio Therapeutics, reports the acquisition of stock options.

Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, acquired 29,800 stock options on September 30, 2024, at an exercise price of $5.03.

Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, acquired stock options on September 30, 2024.

Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, acquired a $20 million convertible note through GKCC, LLC, convertible into approximately 3,442,341 shares of common stock.

Director Jay Venkatesan reports the acquisition of common and pre-funded warrants in Elicio Therapeutics, Inc.

Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, and GKCC, LLC, also a 10% owner, reported the acquisition of common and pre-funded warrants exercisable into Elicio Therapeutics common stock.

Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, reported the acquisition of pre-funded warrants exercisable for over 1 million shares of common stock.